Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV

NCT00305188 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00305188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00305188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2005
Completion date
October 31, 2009
Enrollment
879 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, colorectal neoplasms, metastases